Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxyurea in children: present and future

E P Vichinsky1

  • 1Department of Hematology/Oncology and the Sickle Cell Center, Children's Hospital Oakland, CA 94609, USA.

Seminars in Hematology
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells.

Immunohematology·2012
Same author

Hemoglobin Hakkari: an autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene.

Pediatric blood & cancer·2009
Same author

Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function.

British journal of haematology·2006
Same author

Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.

Journal of pediatric hematology/oncology·2002
Same author

Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease.

The Journal of pediatrics·2001
Same author

Universal newborn screening for Hb H disease in California.

Genetic testing·2001
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Hydroxyurea (HU) shows promise in treating sickle cell disease (SCD) in children by improving hemoglobin levels and preventing organ damage. Long-term safety studies are needed to address potential risks in pediatric patients.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Sickle Cell Disease Research

Background:

  • Sickle cell anemia (SCD) causes progressive organ damage in children.
  • Hydroxyurea (HU) is a potential therapeutic agent for managing SCD complications.
  • Early intervention with HU in infants may alter disease progression and phenotype.

Purpose of the Study:

  • To assess the efficacy of hydroxyurea (HU) in preventing complications and organ damage in children with sickle cell disease (SCD).
  • To evaluate the potential of HU to inhibit organ dysfunction and alter the clinical phenotype of SCD in infants.
  • To examine the impact of HU on hemoglobin F (HbF) levels and red blood cell/endothelial adhesion receptors.

Main Methods:

  • Review of six pediatric trials involving severely ill SCD patients treated with standard HU doses.

Related Experiment Videos

  • Analysis of reported changes in HbF, mean corpuscular volume, and hemoglobin levels.
  • Consideration of ongoing and planned pediatric multicenter trials.

    • Main Results:

    • Consistent clinical response to HU observed in pediatric SCD patients.
    • Significant improvements in HbF and mean corpuscular volume reported across studies.
    • Mild to marked increases in hemoglobin levels noted with HU treatment.

    Conclusions:

    • Hydroxyurea (HU) demonstrates consistent efficacy in improving hematological parameters and clinical response in children with sickle cell disease (SCD).
    • Early initiation of HU in infants may offer significant benefits in preventing organ damage and altering disease trajectory.
    • Further long-term studies are crucial to evaluate the safety profile of HU, including risks like carcinogenesis and growth retardation, in pediatric populations.